SCHEMBL6033461

SCHEMBL6033461

CN(C)c1ccc(SC2=NCCCS2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 8/20 0.37
TSHR P16473 4/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 4/20 0.35
TDP1 Q9NUW8 4/20 0.35
POLB P06746 1/20 0.35
CNR2 P34972 1/20 0.34
RAB9A P51151 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033049 0.83 MAPT (0.46) MAPTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL6033404 0.79 ALDH1A1 (0.41) MAPTSMN1; SMN2ALDH1A1ALOX15LMNA
SCHEMBL6032247 0.79 NOS3 (0.35) MAPTALDH1A1TSHRLMNARAB9A
SCHEMBL6032664 0.79 TSHR (0.43) MAPTTSHRHSD17B10LMNARAB9A
SCHEMBL6033318 0.79 SMN1; SMN2 (0.36) MAPTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL6033067 0.79 ALDH1A1 (0.41) MAPTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL6033133 0.79 PTGIR (0.43) MAPTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL6032640 0.73 GFER (0.52) MAPTSMN1; SMN2ALDH1A1LMNATDP1
SCHEMBL6033077 0.72 HAO1 (0.40) MAPTLMNATDP1RAB9ANOS3
SCHEMBL5701837 0.71 ALDH1A1 (0.65) MAPTSMN1; SMN2ALDH1A1TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084137-B2 Thiazines and thiazoles as agents for protecting materials BAYER AKTIENGESELLSCHAFT (DE) 2006-08-01 US claimed
US-20040204405-A1 Thiazines and thiazoles as agents for protecting materials LANXESS DEUTSCHLAND GMBH (DE) 2004-10-14 US claimed
EP-1437940-A1 THIAZINES AND THIAZOLES FOR USE AS MATERIAL PROTECTIVE AGENTS Bayer Chemicals AG (DE) 2004-07-21 EP claimed
US-20030129081-A1 Thiazines and thiazoles as agents for protecting materials BAYER AKTIENGESELLSCHAFT (DE) 2003-07-10 US claimed
WO-2003001913-A1 THIAZINES AND THIAZOLES FOR USE AS MATERIAL PROTECTIVE AGENTS BAYER CHEMICALS AG (DE) 2003-01-09 WO claimed
US-7084137-B2 Thiazines and thiazoles as agents for protecting materials BAYER AKTIENGESELLSCHAFT (DE) 2006-08-01 US disclosed
US-20040204405-A1 Thiazines and thiazoles as agents for protecting materials LANXESS DEUTSCHLAND GMBH (DE) 2004-10-14 US disclosed
EP-1437940-A1 THIAZINES AND THIAZOLES FOR USE AS MATERIAL PROTECTIVE AGENTS Bayer Chemicals AG (DE) 2004-07-21 EP disclosed
US-20030129081-A1 Thiazines and thiazoles as agents for protecting materials BAYER AKTIENGESELLSCHAFT (DE) 2003-07-10 US disclosed
WO-2003001913-A1 THIAZINES AND THIAZOLES FOR USE AS MATERIAL PROTECTIVE AGENTS BAYER CHEMICALS AG (DE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129081-A1 Thiazines and thiazoles as agents for protecting materials POT1, NAT1, GPX1 MAPT 2345/4885SMN1; SMN2 1705/4885ALDH1A1 40/4885
US-20040204405-A1 Thiazines and thiazoles as agents for protecting materials POT1, NAT1, GPX1 MAPT 2345/4885SMN1; SMN2 1705/4885ALDH1A1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.